First off, it's important to clarify a clear distinction between Prana (PBT) and Patrys (PAB).
Prana: Theoretical chemical reduction of unwanted protein build up. The chemical is an analogue (highly similar to) dyes, resins, etc... not something I'll let willingly put in a person without damn good cause (and data, with p values). But still, it MAY work, and if it does...fantastic. My advice, IF HOLDING - DON'T SELL. There may be a dead cat bounce to come...may.
Patrys: a proven natural human immune response to unwanted cells. Natural Human Antibodies are tried and tested, it's where the industry started in the first place. But now, with advancements in the production of the antibody class Immunoglobulin M (IgM) it's financially possible to produce mass quantities competitively. Safe, proven, natural. Leveraging recent developments in production technology (for example the PER.C6 cell line) is producing dramatic cost savings in the economies of scale. Patry's is boasting 1<2grams/litre, which for a IgM is very, very good. Safe, targeted, works on it's own, and is even better in a combo...Amgen wants that combo.
The relevant clinical trial, which was modestly stated by the CEO Dr. Roskrow as "favourably comparative", to Patrys's product reveals some striking differences. It's very interesting that Dr. Roskrow would drop this comparative bread crumb...
As stated before,
Elotuzumab later resulted in a $30M upfront payment, and up to $680M in royalties depending on milestones.
Patrys's currently sitting on a $30M market cap, with $10M cash in bank.
The differences in study design, IMHO, show a more controlled and considered approach for Patrys than Elotuzumab. Smaller study (lower costs), smaller dosing (lower costs, lower risk) yet Patrys achieved superior biological results... a fantastic and promising result.
- Forums
- ASX - By Stock
- PAB
- amgen's additional $3 billion a year...
amgen's additional $3 billion a year..., page-22
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
-0.003(41.7%) |
Mkt cap ! $6.172M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.3¢ | $57.83K | 15.24M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
36 | 23419058 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 18963224 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 16502123 | 0.003 |
22 | 29062999 | 0.002 |
8 | 12501998 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 18963224 | 7 |
0.005 | 24028833 | 9 |
0.006 | 3329430 | 5 |
0.007 | 449941 | 2 |
0.008 | 1221910 | 4 |
Last trade - 11.12am 02/10/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
The Watchlist
BM8
BATTERY AGE MINERALS LTD
Nigel Broomham, CEO
Nigel Broomham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online